Clinical Trials Logo
NCT number NCT01120171
Study type Interventional
Source Hellenic Oncology Research Group
Contact
Status Terminated
Phase Phase 2
Start date September 2009
Completion date May 2015

Clinical Trial Summary

This study will evaluate the efficacy, safety and effect on quality of life of liposomal-encapsulated doxorubicin in combination with cyclophosphamide as first or second line treatment of older patients (≥ 70 years old) with metastatic breast cancer. The efficacy of the combination will be correlated with the functional status of patients according to the comprehensive geriatric assessment


Clinical Trial Description

Elderly individuals make up a large part of the breast cancer population. When treated with chemotherapy for metastatic disease they derive similar benefits to their younger counterparts. Anthracyclines are associated with a cumulative dose-dependent cardiomyopathy with increased rate in patients over the age of 70. Liposomal-encapsulated doxorubicin improves the therapeutic index of doxorubicin by reducing significantly the cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for metastatic breast cancer


Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


See also
Status Clinical Trial Phase
 Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data N/A
 Recruiting NCT01857193 - Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer Phase 1
 Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A
 Active, not recruiting NCT02371174 - Post-Marketing Surveillance Study of Eribulin on the Status and Factors for the Development of Peripheral Neuropathy in Japan. N/A
 Recruiting NCT01967823 - T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer Phase 2
 Recruiting NCT02739425 - The Efficacy of Sentimag in Detection of Sentinel Node Biopsy N/A
 Recruiting NCT02903524 - Doxorubicin Hydrochloride Liposome Injection Combination With Cyclophosphamide vs Pirarubicin Combination With Cyclophosphamide in Patients With Locally Advanced Breast Cancer Phase 4
 Recruiting NCT02689427 - Phase IIB Neoadjuvant Enzalutamide (ZT) Plus Taxol for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer (AR+ TNBC) Phase 2
 Recruiting NCT02897544 - Integrative Approaches for Cancer Survivorship 2: Project 2 N/A
 Recruiting NCT03080155 - A Study of the 3D MIRA System in Classifying Women at for Likelihood of Breast Cancer N/A
 Recruiting NCT02934126 - The Development of a Personalized Decision Aid: Perspectives of Patients and Health Care Professionals on Shared Decision Making and Informational Needs on Radiotherapy for Breast Cancer N/A
 Recruiting NCT02980848 - Assessing Breast Density's Value in Imaging - A Comparative Effectiveness Study N/A
 Recruiting NCT02897635 - Integrative Approaches For Cancer Survivorship 2: Project 1 N/A
 Recruiting NCT02035085 - 19F Hot Spot MRI of Human Adipose-derived Stem Cells for Breast Reconstruction Phase 1
 Recruiting NCT02840344 - Couples-Based Mindfulness for Young Breast Cancer Survivors N/A
 Recruiting NCT02913729 - Pre- Versus Postoperative Accelerated Partial Breast Irradiation N/A
 Recruiting NCT02929576 - Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer Phase 3
 Recruiting NCT02894398 - Efficacy/Quality of Life Study of Postmenop. Women With Advanced Breast Cancer, Treated With Letrozol and Palbociclib Phase 2
 Recruiting NCT02875626 - Role of Indocyanine Green (ICG) for Detection of Sentinel Nodes in Breast Cancer N/A
 Recruiting NCT02909751 - Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer Phase 2